Open AccessESBL and MBL in Cefepime Resistant Pseudomonas aeruginosa : An Update from a Rural Area in Northern India
Author(s) -
Aarti Kotwal,
Debasis Biswas,
Barnali Kakati,
Malvika Singh
Publication year - 2016
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2016/18016.7612
Subject(s) - cefepime , cefoperazone , amikacin , piperacillin , pseudomonas aeruginosa , medicine , microbiology and biotechnology , imipenem , ceftazidime , cephalosporin , ciprofloxacin , tazobactam , sulbactam , antibiotics , antibiotic resistance , biology , bacteria , genetics
Cefepime, a fourth generation cephalosporin, is widely used for the empirical treatment of serious infections in critically ill hospitalized patients. Pseudomonas aeruginosa (P. aeruginosa), one of the commonest bacteria causing nosocomial infections has a propensity to develop antibiotic resistance quite promptly.